Zealand, Roche’s Obesity Drug Helps Patients Lose up to 9.2% Weight in Mid-Stage Trial

Zealand, Roche's obesity drug helps patients lose up to 9.2 ...

Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle

Zealand Pharma and Roche rolled out some mid-stage data for their amylin drug in obesity and diabetes, hoping to compete with Eli Lilly. In a Phase 2 study, petrelintide reduced patients’ ...

Another bad day at Zealand: Roche-partnered drug disappoints on blood sugar - European Biotechnology Magazine

Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood sugar control. It's the second positive trial readout that has failed to reassure investors in the course of a week.

Zealand Pharma reports Phase 2 petrelintide weight loss

The 220-person ZUPREME-2 trial also showed improved HbA1c; Zealand says the first participants have begun treatment in its Phase 3a program.

Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.